Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.48 |
| ▸ | CA2 | P00918 | 9/20 | 0.48 |
| ▸ | CA12 | O43570 | 5/20 | 0.48 |
| ▸ | CA9 | Q16790 | 5/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | PRKCB | P05771 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | LYN | P07948 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL4337526 | 0.93 | CA12 (0.47) | CA1CA2CA12CA9SCN9A | |
| SCHEMBL3833950 | 0.91 | CA12 (0.48) | CA1CA2CA12CA9SCN9A | |
| SCHEMBL13925821 | 0.78 | SCN9A (0.51) | CA1CA2CA12CA9SCN9A | |
| SCHEMBL30688720 | 0.76 | CA12 (0.49) | CA1CA2CA12CA9SCN9A | |
| SCHEMBL30345053 | 0.74 | KDM4E (0.59) | CYP3A4KDM4EL3MBTL1 | |
| SCHEMBL25717389 | 0.74 | KDM4E (0.59) | CYP3A4KDM4EL3MBTL1 | |
| SCHEMBL30336602 | 0.74 | KDM4E (0.59) | CYP3A4KDM4EL3MBTL1 | |
| SCHEMBL7336799 | 0.73 | CA12 (0.56) | CA1CA2CA12CA9SCN9A | |
| SCHEMBL30599177 | 0.72 | SCN9A (0.49) | CA1CA2CA12CA9SCN9A | |
| SCHEMBL26251803 | 0.72 | SCN9A (0.49) | CA1CA2CA12CA9SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050249662-A1 | Marked maleimide compounds, method for preparing same and use thereof for marking macromolecules | COMMISSARIAT A L'ENERGIE (FR) | 2005-11-10 | — | — | US | claimed |
| EP-1517903-A2 | MARKED MALEIMIDE COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR MARKING MACROMOLECULES | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2005-03-30 | — | — | EP | claimed |
| WO-2004002984-A2 | MARKED MALEIMIDE COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR MARKING MACROMOLECULES | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2004-01-08 | — | — | WO | claimed |
| US-10471161-B2 | Vinylsulfone-based 18F-labeling compositions and methods and uses thereof | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2019-11-12 | — | — | US | disclosed |
| US-20160015838-A1 | Vinylsulfone-based 18F-labeling Compositions and Methods and Uses Thereof | UNIVERSITY OF SOUTHERN CALIFORNIA USC STEVENS (US) | 2016-01-21 | — | — | US | disclosed |
| WO-2009033876-A1 | APTAMERS LABELED WITH 18F | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-19 | — | — | WO | disclosed |
| EP-2036981-A1 | Aptamers labeled with 18F | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-18 | — | — | EP | disclosed |
| US-7456202-B2 | Marked maleimide compounds, method for preparing same and use thereof for marking macromolecules | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2008-11-25 | — | — | US | disclosed |
| US-20050249662-A1 | Marked maleimide compounds, method for preparing same and use thereof for marking macromolecules | COMMISSARIAT A L'ENERGIE (FR) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050249662-A1 | Marked maleimide compounds, method for preparing same and use thereof for marking macromolecules | CRBN, NR2E3, NR2C2 | CA1 470/4885CA2 1967/4885CA12 211/4885 |
| US-20160015838-A1 | Vinylsulfone-based 18F-labeling Compositions and Methods and Uses Thereof | TST, VARS1, STS | CA1 3847/4885CA2 4778/4885CA12 3587/4885 |
| US-10471161-B2 | Vinylsulfone-based 18F-labeling compositions and methods and uses thereof | TST, VARS1, STS | CA1 3847/4885CA2 4778/4885CA12 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.